Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.64 |
| ▸ | JAK3 | P52333 | 10/20 | 0.64 |
| ▸ | JAK1 | P23458 | 7/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 8/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.37 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099444 | 0.84 | JAK2 (0.61) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL10099360 | 0.78 | JAK2 (0.64) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL10099361 | 0.78 | JAK2 (0.64) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL566639 | 0.78 | JAK3 (1.00) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL574987 | 0.78 | JAK3 (1.00) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL10099449 | 0.77 | JAK3 (0.82) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL10099415 | 0.75 | JAK3 (0.78) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL10099453 | 0.73 | JAK3 (0.76) | JAK2JAK3JAK1ROCK2ROCK1 | |
| SCHEMBL10099446 | 0.72 | JAK3 (0.67) | JAK2JAK3JAK1ROCK1TYK2 | |
| SCHEMBL566425 | 0.69 | JAK3 (0.83) | JAK2JAK3JAK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.